Cannabidiol 133mg + Cannabigerol 66mg + Tetrahydrocannabinol 4mg vs Placebo as Adjuvant Treatment in Chronic Migraine - (CAMTREA)

Randomized, Double Blind Clinical Trial to Study the Effect of Cannabidiol (CBD) 133mg + Cannabigerol (CBG) 66mg + Tetrahydrocannabinol (THC) 4mg a Day as Adjunctive Therapy in the Treatment of Chronic Migraine - CAMTREA TRIAL

To evaluate the effect of the cannabidiol (CBD) + cannabigerol (CBG) + tetrahydrocannabinol (THC) up to 133/66/4mg daily versus placebo as adjuvant treatment in chronic migraine (CM) patients under preventive treatment at a stable dose for at least 3 months who present at least 5 headaches day a month. CM patients of both sexes, between 25 and 65 years old, who have not had CBD and/or THC as a migraine treatment. Patients may be having migraine preventive treatment such as propranolol, atenolol, topiramate, valproic acid/sodium valproate, levetiracetam, gabapentin, lamotrigine, pre-gabaline, flunarizine, amitriptyline, nortriptyline, clomipramine, candesartan, galcanezumab, erenumab, fremanezumab, botulinum toxin type A. Acute treatment will follow patients doctor's prescription. Exclusion criteria: active liver disease or elevated liver transaminases> 3 times than the normal values, pregnancy, fertile age women without contraceptive treatment or who intend to get pregnant, patients without migraine preventive treatment or that changed the preventive treatment less than 3 months from the study start, substance abuse or addiction, use of medical cannabis or products with CBD or THC in the last 30 days or during study period, history of allergy or adverse reactions with the use of CBD or related products, substance users of liver enzymes inducers such as rifampicin, ketoconazole, theophylline, carbamazepine, phenytoin, phenobarbital and St. John's wort, clobazam, macrolides, verapamil, fluoxetine, amiodarone and tacrolimus. Patients on vitamin K anticoagulant medicines, as warfarin.

Randomization using a computacional system will stratify participants in each group by gender (F/M), age (25-34/35-44/45-54/55-65yo), headache days presented in the baseline month (5-10/11-15/16-20/21-25/26-30), overuse medication (yes or no). After randomization patients will be divided into two groups of 55 participants, who will receive CBD + CBG + THC up to a maximum daily dose of 133/66/4 mg or placebo for 12 weeks (V0 screening, V1 allocation, V4 final visit).

The main outcome is the reduction in frequency of headache days per 4 weeks between V1 and V4 compared to placebo. Secondary outcomes will be a reduction in duration and intensity of migraine attacks, amount of painkillers used and percentage of patients with a reduction greater than 50% on migraine days, 50% reduction in the other variables as MIDAS scores, HIT-6 scores, Beck's Anxiety and Depression Scales, Epworth Sleepiness Scales, and the scores at The Severity of Dependence Scale used as an indicator of overuse medication in this sample.

Clinical data will be registered on a personalized headache diary developed to this study using MyCap, from RedCap System, as an APP for daily entries using smartphones, androids or IOS system.

The clinical and laboratory data obtained in this study will comply with the objectives elaborated in the evaluation of the primary and secondary endpoints, the proposal of which is to publish the data regardless of the results obtained.

Study Overview

• Status: Recruiting
• Conditions: Chronic Migraine, Headache; Overuse Headache Medication
• Intervention / Treatment: Drug: Cannabidiol + Cannabigerol + Tetrahydrocannabinol 133/66/4mg; Drug: Placebo oral drops

• Study Type: Interventional
• Enrollment (Anticipated): 110
• Phase: Phase 4

Contacts and Locations

• Study Contact: Name: Fernanda Assir; Phone Number: +55 11 21510724; Email: fernanda.assir@einstein.br

Study Locations

• Brazil
  • São Paulo, Brazil, 05653120
    • Recruiting
    • Centro de Pesquisa Clinica Hospital Israelita Albert Einstein
    • Contact: Fernanda A Victoriano; Phone Number: +5511983373750; Email: camtreatrial@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 25 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients of both sexes, 25 to 65 years old, with chronic migraine according to IHS Classification System, 3rd edition
• Undergoing preventive treatment in a stable dose of the preventive medication for at least 2 months, who have not used cannabidiol to treat migraine.
• At least 5 days of migraine/migraine like attacks in the baseline period (4 weeks)
• As preventive drugs propranolol, atenolol, topiramate, valproic acid/sodium valproate, levetiracetam, gabapentin, lamotrigine, pre-gabaline, flunarizine, amitriptyline, nortriptyline, clomipramine, candesartan, galcanezumab, erenumab, fremanezumab, botulinum toxin type A will be allowed. Patients whose preventive treatment for migraine is Botulinum Toxin Type A may participate in the study as long as the toxin application interval used is 4 months (duration of medication or placebo use) and who have already received treatment with toxin at least 2 times.
• If acute treatment is necessary, patients may use the medications as previously advised by the physician accompanying them, and may use common, combined painkillers, anti-inflammatory drugs, triptans, triptans combined with anti-inflammatory drugs, opioid analgesics.

Exclusion Criteria:

• Patients with active liver disease
• pregnancy and/or women who intend to become pregnant or who do not make adequate use of contraceptive therapy/methods
• breastfeeding women
• use of cannabis during the study, whether with therapeutic or recreational intentions
• patients who are without preventive treatment or who have undergone a dose change in preventive migraine treatment less than two months before V1 .
• Patients whose exclusive treatment for chronic migraine is Botulinum Toxin Type A at intervals of less than 4 months.
• History of substance abuse or addiction, use of medical cannabis or products with CBD, CBG or THC in the last 30 days, history of allergy to CBD or related products
• elevated transaminases > 3x the normal value
• substance abusers
• patients using substances that are potent enzyme inducers, such as rifampicin, ketoconazole, theophylline, carbamazepine, phenytoin, phenobarbital and St. John's wort, clobazam, macrolides, verapamil, fluoxetine, amiodarone and tacrolimus.
• Patients using anticoagulant, like vitamin K anticoagulant medicines, as warfarin.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Cannabidiol + Cannabigerol + Tetrahydrocannabinol 133/66/4mg; Cannabidiol + Cannabigerol + Tetrahydrocannabinol in the maximum dosage of 133/66/4mg, divided in 2 doses of 66.5/33/2mg a day for 12 weeks. Each drop contain CBD/CBG/THC 1.66/0.8/0.05 mg, and medication will be titrated up as follow: day 1 to day 3 - 10 drops twice a day day 4 to day 6 - 20 drrops twice a day day 7 to day 9 - 30 drops twice a day from day 10 to the end of the study 40 drops twice a day	Drug: Cannabidiol + Cannabigerol + Tetrahydrocannabinol 133/66/4mg; use of cannabidiol + canabigerol + thc for 12 weeks
Placebo Comparator: Placebo; Placebo capsules will be titrated up as follow: day 1 to day 3 - 10 drops twice a day day 4 to day 6 - 20 drops twice a day day 7 to day 9 - 30 drops twice a day from day 10 to the end of the study 40 drops twice a day	Drug: Placebo oral drops; use of placebo for 12 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Migraine days	The primary outcome will be the reduction in migraine days observed between the baseline period (4 weeks before randomization) and the final visit 12 weeks of intervention (CBD+CBG+THC or placebo)	16 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Headache days	The primary outcome will be the reduction in headache days observed between the baseline period (4 weeks before randomization) and the final visit 12 weeks of intervention (CBD+CBG+THC or placebo)	12 weeks
migraine duration	the attack duration in hours observed before and after the intervention (CBD+CBG+THC or placebo)	12 weeks
migraine intensity	the migraine attack intensity measured in a 3 point scale (1- mild; 2 - moderate; 3 - severe) before and after the intervention (CBD+CBG+THC or placebo)	12 weeks
pain medicine intake	the amount of pain medicine intake as needed before and after the intervention (CBD+CBG+THC or placebo)	12 weeks
number of patients with migraine reduction greater than 50%	the number of patients with migraine reduction greater than 50% before and after the intervention (CBD+CBG+THC or placebo)	12 weeks
number of patients with headache reduction greater than 50%	the number of patients with migraine reduction greater than 50% before and after the intervention (CBD+CBG+THC or placebo)	12 weeks
Change in MIDAS score	the observed change in MIDAS score, before and after the intervention (CBD+CBG+THC or placebo)	12 weeks
Change in HIT-6 score	the observed reduction in HIT-6 score, before and after the intervention (CBD+CBG+THC or placebo)	12 weeks
Change in Beck's Anxiety Inventory scores	the observed change in BAI score, before and after the intervention (CBD+CBG+THC or placebo)	12 weeks
Change in Beck's Depression Inventory scores	the observed change in BDI score, before and after the intervention (CBD+CBG+THC or placebo)	12 weeks
Change in Severity of Dependence Scale scores	the observed change in SDS score, before and after the intervention (CBD+CBG+THC or placebo)	12 weeks
Change in Epworth Sleepiness Scale scores	the observed change in Epworth score, before and after the intervention (CBD+CBG+THC or placebo)	12 weeks

Collaborators and Investigators

• Sponsor: Hospital Israelita Albert Einstein
• Collaborators: Industria Farmacêutica Health Meds
• Investigators: Principal Investigator: Alexandre O Kaup, MD, PhD, Clinical Research Hospital Israelita Albert Einstein, Neurologist

Study record dates

Study Major Dates

• Study Start (Actual): October 18, 2022
• Primary Completion (Anticipated): October 18, 2023
• Study Completion (Anticipated): April 19, 2024

Study Registration Dates

• First Submitted: May 24, 2021
• First Submitted That Met QC Criteria: August 3, 2021
• First Posted (Actual): August 4, 2021

Study Record Updates

• Last Update Posted (Estimate): January 16, 2023
• Last Update Submitted That Met QC Criteria: January 12, 2023
• Last Verified: January 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Pain; Neurologic Manifestations; Headache Disorders, Primary; Headache Disorders; Migraine Disorders; Headache; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Peripheral Nervous System Agents; Analgesics; Sensory System Agents; Analgesics, Non-Narcotic; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Psychotropic Drugs; Anticonvulsants; Hallucinogens; Cannabinoid Receptor Agonists; Cannabinoid Receptor Modulators; Dronabinol; Cannabidiol
• Other Study ID Numbers: HIAE CAMTREA Protocol

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No